p53 antibody | knockout validation | Cell Signaling 18032

This is a knockout-validated antibody summary, based on the publication "A Dominant-Negative Effect Drives Selection of TP53 Missense Mutations in Myeloid Malignancies", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Mouse monoclonal IgG2a

Company: Cell Signaling

Antibody: p53

Catalog number: 18032

Summary: Mouse monoclonal IgG2a against a recombinant human wild type p53 protein expressed in E. coli. Reacts with human by western blot.

Validation Method

Western blot

Sample

Control and p53−/− MOLM13 cells.

Secondary incubation

Goat anti-mouse HRP (Genesee Scientific, #20-304).

Detection

SuperSignal™ West Dura Extended Duration Substrate (ThermoFisher, # 34075).

Figure

MOLM13-TP53 isogenic AML cell lines with p53+/+, p53+/−, and p53−/− as well as p53R248Q/+ and p53R248Q/– were treated with DMSO (–) or 100 nM daunorubicin (+) for 6 hours, after which whole-cell protein lysates were collected, run on a polyacrylamide gel, and immunoblotted for p53, p21, and actin (replicates, n = 3; representative images are shown). Please see Figure 3a in the article [1].

References

Boettcher S, Miller P, Sharma R, McConkey M, Leventhal M, Krivtsov A, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365:599-604 pubmed publisher

contribute

If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.